Avirmax Biopharma Initiates IND-enabling Studies of ABI-201; a Breakthrough Gene Therapy for Dry Age-related Macular Degeneration

Gilbert Sun News

Kingman Miner

View article

bluemountaineagle.com

View article

Lompoc Record

Center

View article

Clearwater Progress

View article

Eastern Progress

View article

portlandtribune.com

Lean Left

View article

+6 Reposted by 6 other sources

Center

Factuality

Ownership

Avirmax Biopharma Initiates IND-enabling Studies of ABI-201; a Breakthrough Gene Therapy for Dry Age-related Macular Degeneration

HAYWARD, Calif., Feb. 28, 2025 /PRNewswire/ -- Avirmax Biopharma, Inc., a leader in developing the next generation of AAV gene therapies, today announced the commencement of Investigational New Drug (IND)-enabling studies of ABI-201, a potential first-in-class AAV vector that delivers…

El Independiente

Factuality

Ownership

This week Madrid hosted the national awareness campaign ‘Vision on Wheels’, an initiative by Bayer to raise awareness of the impact of ophthalmological diseases such as the Macular Degeneration Associated with the Neovascular Age (DMAEn) and the Diabetic Macular Edema (EMD), which in Spain affect more than half a million people. After passing through Seville, Valencia and Barcelona, among other cities, Madrid is the ninth stop of a tour that wil…

pipelinereview

Factuality

Ownership

Avirmax Biopharma Initiates IND-enabling Studies of ABI-201; a Breakthrough Gene Therapy for Dry Age-related Macular Degeneration - Pipelinereview

HAYWARD, CA, USA I February 28, 2025 I Avirmax Biopharma, Inc., a leader in developing the next generation of AAV gene therapies, today announced the commencement of Investigational New Drug (IND)-enabling studies of ABI-201, a potential first-in-class AAV vector that delivers three genes to correct the dysregulation of complement activation, anti-inflammation, to protect retinal pigment epithelia and photoreceptors as well as to block retinal n…